Channel Therapeutics Corpora
13F holders, Q2 2024 (June 30)5holders +4
4new positions
0sold out
1famous investor
$1.32avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Channel Therapeutics Corpora in their 13F filings, up 4 from Q1 2024. 4 opened new positions and 0 sold out. The largest holders were Anson Funds Management LP ($265K), Citadel Advisors ($25K) and UBS Group AG ($246). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Channel Therapeutics Corpora
- Filed as
- CHROMOCELL THERAPEUTICS CORP (Q2 2024)
- CUSIP
- 171126105
- Latest filing quarter
- Q2 2025
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $25K |
| Exits | 0 | $0 |
All 13F filers, Q1 2024 → Q2 2024: 18,915 shares bought and 50,858 shares sold, net −31,943 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Anson Funds Management LP | 0.04% | Reduce -20.2% | 201,030 | $265K |
| Citadel Advisors | 0.00% | New | 18,714 | $25K |
| UBS Group AG | 0.00% | New | 186 | $246 |
| Bank of America Corp. | 0.00% | New | 9 | $12 |
| Tower Research Capital LLC (TRC) | 0.00% | New | 6 | $8 |
"% of holder's portfolio" is CHANNEL THERAPEUTICS CORPORA's weight in each manager's 13F, not the share of Channel Therapeutics Corpora the manager owns.